CLINICAL TRIALS PROFILE FOR INSULIN LISPRO RECOMBINANT

505(b)(2) Clinical Trials for Insulin Lispro Recombinant

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT02942654 ↗	A Study of LY900014 Formulation in Healthy Participants	Completed	Eli Lilly and Company	Phase 1	2016-11-01	This study evaluates a new formulation of LY900014, a drug that lowers blood sugar. It is administered by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will last about 6 to 7 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.
New Formulation	NCT03232983 ↗	A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants	Completed	Eli Lilly and Company	Phase 1	2017-08-14	This study evaluates a new formulation of insulin lispro, LY900014, a drug that lowers blood sugar. It is administered by injection into the vein and under the skin of the abdomen, thigh and arm. The study will be conducted in healthy people to investigate the effect of different injection sites on the amount of insulin lispro in the bloodstream. Side effects and tolerability will be documented. The study will last for about 10 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.
New Formulation	NCT04049123 ↗	A Study of LY900014 in Healthy Chinese Participants	Completed	Eli Lilly and Company	Phase 1	2019-11-18	The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014 and the affect of LY900014 on blood sugar levels. For each participant, the study will consist of 3 periods and will last about 51 days.
New Formulation	NCT04161976 ↗	A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus	Completed	Eli Lilly and Company	Phase 1	2019-12-27	The main purpose of this study is to learn more about a new formulation of insulin lispro when given by an insulin pump to participants with type 1 diabetes mellitus. The study will investigate how the body processes the drug and how the drug affects the body. Information about side effects will be collected. The study will last from six to 12 weeks for each participant.

All Clinical Trials for Insulin Lispro Recombinant

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00036504 ↗	Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin	Completed	Eli Lilly and Company	Phase 4	2001-08-01	The purposes of this study are to determine: 1. If patients taking insulin lispro LM with metformin will have better overall control of their blood sugar than patients taking a long acting insulin comparator with metformin. 2. If there is a difference in the way the two treatments affect blood sugar control before and after meals and at night. 3. If there is a difference in the insulin dose required with the two treatments. 4. If there is a difference in the numbers of times patients experience low blood sugar with the two treatments. 5. If there is a difference in the effect on patients's body weight.
NCT00046501 ↗	Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents	Completed	Sanofi	Phase 3	2002-11-01	The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast acting insulin (Lispro)
NCT00071448 ↗	Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population	Completed	Novo Nordisk A/S	Phase 3	2002-06-01	This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
NCT00095446 ↗	NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes	Completed	Novo Nordisk A/S	Phase 4	2004-07-01	This trial is conducted in the United States of America (USA). The aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in standard clinical practice.
NCT00097071 ↗	Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents	Completed	Novo Nordisk A/S	Phase 3	2004-10-01	This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes. Insulin Aspart (NovoLog®) is an ideal insulin to use in an intensive insulin regimen using continuous subcutaneous insulin injection (CSII) therapy in the pediatric and adolescent age population. This trial compares the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered by CSII in children and adolescents with type 1 diabetes.

Clinical Trial Conditions for Insulin Lispro Recombinant

Condition Name

Condition Name for Insulin Lispro Recombinant
Intervention	Trials
Type 1 Diabetes Mellitus	42
Diabetes Mellitus, Type 1	41
Diabetes Mellitus, Type 2	37
Type 2 Diabetes Mellitus	18

Condition MeSH

Condition MeSH for Insulin Lispro Recombinant
Intervention	Trials
Diabetes Mellitus	192
Diabetes Mellitus, Type 1	119
Diabetes Mellitus, Type 2	71
Hyperglycemia	10

Clinical Trial Locations for Insulin Lispro Recombinant

Trials by Country

Trials by Country for Insulin Lispro Recombinant
Location	Trials
United States	874
Germany	110
China	71
Canada	45
Mexico	42

Trials by US State

Trials by US State for Insulin Lispro Recombinant
Location	Trials
California	58
Texas	49
Florida	43
Georgia	36
New York	35

Clinical Trial Progress for Insulin Lispro Recombinant

Clinical Trial Phase

Clinical Trial Phase for Insulin Lispro Recombinant
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Insulin Lispro Recombinant
Clinical Trial Phase	Trials
Completed	188
Not yet recruiting	11
Recruiting	11

Clinical Trial Sponsors for Insulin Lispro Recombinant

Sponsor Name

Sponsor Name for Insulin Lispro Recombinant
Sponsor	Trials
Eli Lilly and Company	93
Sanofi	25
Adocia	22

Sponsor Type

Sponsor Type for Insulin Lispro Recombinant
Sponsor	Trials
Industry	231
Other	102
U.S. Fed	2

Clinical Trials Update, Market Analysis, and Projection for Insulin Lispro Recombinant

Last updated: October 30, 2025

---

Introduction

Insulin Lispro Recombinant, branded as Humalog by Eli Lilly and other biosimilars globally, is a rapid-acting insulin formulation pivotal in diabetes management. As the global prevalence of diabetes surges—projected to reach 700 million individuals by 2045 [1]—the demand for effective, fast-acting insulins escalates. Continuous innovation enhances the therapeutic landscape, with clinical trials and market dynamics shaping future accessibility and profitability. This report synthesizes recent clinical trial developments, current market conditions, and projections to inform business decisions.

---

Clinical Trials Update

Recent Clinical Trials

The primary focus of recent investigations into Insulin Lispro Recombinant centers on optimizing efficacy, safety, and delivery methods:

• Phase IV Post-Marketing Studies: Eli Lilly and competitors initiated extensive studies assessing long-term safety profiles, particularly hypersensitivity reactions and hypoglycemia risk, in diverse populations, including pediatric, elderly, and pregnant patients [2].

• Biosimilar Development: Several biosimilars, including Semglee (Mylan/Biocon), are undergoing phase III trials to establish biosimilarity and equivalence in pharmacokinetics and pharmacodynamics [3]. These trials aim to reduce costs and expand access.

• Delivery Innovations: Latest trials explore ultra-rapid formulations and artificial pancreas integration. For example, a 2022 trial investigated a high-concentration Lispro formulation coupled with closed-loop insulin pump systems, demonstrating improved postprandial glucose control [4].

• Combination Therapies: Studies combining Insulin Lispro with GLP-1 receptor agonists investigate synergistic effects, aiming to provide comprehensive glycemic control with minimal hypoglycemia risk [5].

Notable Outcomes and Regulatory Progress

• FDA Approvals: Recently, the approval of biosimilar insulin Lispro, such as Mylan's Semglee, demonstrates regulatory confidence, boosting market competition [6].

• Real-World Evidence (RWE): Data from observational studies suggest that rapid-acting insulins, including Lispro, effectively reduce postprandial hyperglycemia, with safety profiles aligning with clinical trial data [7].

---

Market Analysis

Market Size and Growth Drivers

The global insulin market was valued at approximately $25 billion in 2022 and is projected to reach $45 billion by 2030, growing at a CAGR of ~7% [8]. Insulin Lispro, covering roughly 35% of rapid-acting insulin sales, holds a dominant position, driven by:

• Increasing Diabetes Prevalence: Both Type 1 and Type 2 diabetes patients require rapid-acting insulins for basal-bolus regimens.

• Advances in Insulin Formulations: Novel formulations enhancing absorption and reducing injection volume attract prescribers.

• Technological Adoption: Growing acceptance of insulin pumps and continuous glucose monitoring (CGM) systems increases demand for compatible rapid-acting insulins.

Competitive Landscape

Key players include Eli Lilly (Humalog), Novo Nordisk (NovoRapid), Sanofi (Admelog), and biosimilar manufacturers like Mylan and Biocon, competing primarily on price, formulation, and delivery options~[9].

Biosimilars are gaining market share—Semglee, authorized in multiple regions, offers a cost-effective alternative, fostering price competition and expanding access, particularly in emerging markets.

Regulatory and Reimbursement Trends

Increasing acceptance of biosimilars by health authorities, including FDA, EMA, and PMDA, coupled with expanding reimbursement policies, sustains market growth. Cost reduction initiatives are critical, given insulin's high out-of-pocket expense burden in regions like the U.S. [10].

Market Challenges

• Price Sensitivity: Insulin pricing remains a contentious issue, impacting margins and adoption.

• Manufacturing Barriers: Ensuring biosimilar quality and consistency presents technical challenges.

• Patent Expirations: While patents for Humalog expired in 2020, patent protections for certain formulations persist, influencing biosimilar entry.

---

Market Projections

Short-Term (2023–2025)

• Expect accelerated growth in biosimilar insulin Lispro sales, comprising up to 25% of rapid-acting insulin market by 2025.

• Ongoing trial data will bolster regulatory approvals for new formulations and delivery systems.

• Increasing adoption of insulin pumps integrated with digital health solutions will amplify demand.

Mid to Long-Term (2026–2030)

• Market penetration of biosimilars will reach approximately 50%, driven by cost advantages and expanding healthcare infrastructure in emerging economies.

• Emerging formulations, such as ultra-rapid Lispro analogs, could constitute 15% of the rapid-acting insulin segment, contingent on clinical efficacy and regulatory approval.

• Innovating delivery mechanisms—smart pens, closed-loop systems—will render Insulin Lispro more user-friendly, further expanding the patient base.

---

Implications for Stakeholders

Innovator companies must prioritize lifecycle management through new formulations and delivery innovations. Biosimilar entrants should leverage regulatory endorsements and cost advantages to expand market share. Policymakers and payers are motivated to negotiate pricing strategies to improve patient access amid escalating demand.

---

Key Takeaways

• Clinical trials indicate ongoing Progress towards optimizing Insulin Lispro Recombinant’s safety, efficacy, and patient convenience, facilitating regulatory approval of novel formulations and biosimilars.

• The global insulin market, especially rapid-acting types, is poised for sustained growth driven by rising diabetes prevalence, technological integration, and biosimilar competition.

• Biosimilar insulin Lispro products are rapidly gaining market share, exerting downward pressure on prices and increasing access, primarily in regions with expanding healthcare budgets.

• Technological advancements, including integration with digital health tools, will enhance patient adherence and glycemic control, potentially shifting market dynamics.

• Strategic focus on innovation, regulatory navigation, and cost management will define success amidst intensifying competition and evolving healthcare policies.

---

FAQs

1. What are the key clinical advantages of Insulin Lispro Recombinant?
   Its rapid onset of action (peak within 30–90 minutes) allows effective postprandial glucose control, with a shorter duration reducing hypoglycemia risk compared to regular insulin.

2. How might biosimilar versions impact the Insulin Lispro market?
   Biosimilars offer cost-effective alternatives, increasing accessibility and potentially reducing the overall market price, stimulating demand and expanding global reach.

3. Are new formulations of Insulin Lispro in clinical development?
   Yes. Research explores ultra-rapid Lispro analogs and combination therapies, aiming for improved onset, offset, and patient convenience.

4. What delivery innovations are influencing Insulin Lispro utilization?
   Integration into insulin pump systems, smart pens, and closed-loop artificial pancreas systems improves dosing precision, adherence, and glycemic outcomes.

5. What regulatory trends could shape the future of Insulin Lispro?
   Increasing acceptance of biosimilars, expedited review pathways, and approvals for novel formulations will facilitate market expansion and innovation.

---

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 10th Edition, 2021.
[2] FDA Post-Marketing Surveillance Data, 2022.
[3] Biosimilar Development Pipelines, Generic Pharmaceutical Association, 2022.
[4] ClinicalTrials.gov, NCT05269967, 2022.
[5] Journal of Diabetes Science and Technology, 2022.
[6] FDA Approval Document, 2022.
[7] Real-World Evidence in Diabetes Management, Diabetes Therapy, 2022.
[8] MarketsandMarkets. Insulin Market Report, 2022.
[9] GlobalData Healthcare. Diabetes Insulin Market Analysis, 2022.
[10] IQVIA Institute Report, 2022.